SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers
- 1 April 2010
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Drug Targeting
- Vol. 19 (2), 114-124
- https://doi.org/10.3109/10611861003733995
Abstract
Toxoplasmic encephalitis (TE) is the most common clinical manifestation of reactivated infection with Toxoplasma gondii in immunocompromised patients that is lethal if untreated. The combination of pyrimethamine plus sulfadiazine or clindamycin is the standard therapy for the treatment of TE, but these combinations are associated with hematologic toxicity and/or life-threatening allergic reactions. Therefore, alternative treatment options are needed. Atovaquone is safe and highly effective against T. gondii in vitro, but the oral micronized solution shows poor bioavailability. We synthesized atovaquone nanosuspensions (ANSs) coated with poloxamer 188 (P188) and sodium dodecyl sulfate (SDS) to improve oral bioavailability and passage through the blood-brain barrier (BBB). Coating of ANSs with SDS resulted in enhanced oral bioavailability and enhanced brain uptake of atovaquone compared to Wellvone(®) in murine models of acute and reactivated toxoplasmosis as measured by high performance liquid chromatography (HPLC). Parasite loads and inflammatory changes in brains of mice treated with SDS-coated ANS were significantly reduced compared to untreated controls and to Wellvone(®)-treated mice. In conclusion, nanosuspensions coated with SDS may ultimately lead to improvements in the treatment of TE and other cerebral diseases.Keywords
This publication has 33 references indexed in Scilit:
- Atovaquone Maintenance Therapy Prevents Reactivation of Toxoplasmic Encephalitis in a Murine Model of Reactivated ToxoplasmosisAntimicrobial Agents and Chemotherapy, 2004
- Antiparasitic Agent AtovaquoneAntimicrobial Agents and Chemotherapy, 2002
- Randomized Phase II Trial of Atovaquone with Pyrimethamine or Sulfadiazine for Treatment of Toxoplasmic Encephalitis in Patients with Acquired Immunodeficiency Syndrome: ACTG 237/ANRS 039 StudyClinical Infectious Diseases, 2002
- Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: Influence of PEG coating on the particle size, drug release rate and phagocytic uptakeBiomaterials, 2001
- Sodium lauryl sulphate increases tiludronate paracellular transport using human epithelial caco-2 monolayersInternational Journal of Pharmaceutics, 1995
- The Role of Atovaquone Tablets in Treating Pneumocystis carinii PneumoniaJAIDS Journal of Acquired Immune Deficiency Syndromes, 1995
- Epithelial Transport of Drugs in Cell Culture. VIII: Effects of Sodium Dodecyl Sulfate on Cell Membrane and Tight Junction Permeability in Human Intestinal Epithelial (Caco-2) CellsJournal of Pharmaceutical Sciences, 1993
- In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondiiAntimicrobial Agents and Chemotherapy, 1992
- Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondiiAntimicrobial Agents and Chemotherapy, 1991
- Toxoplasma gondii infection of the central nervous systemHuman Pathology, 1981